Table 3.
Summary of key clinical trials in RRMM with previous BOR exposure subgroup.
| Trial | % Previous BOR Exposure | ORR (%) | PFS | OS |
|---|---|---|---|---|
| ASPIRE * KRd vs. K-dex |
62–67 vs. 64–66 | NT for subgroup analysis | NT for subgroup analysis | 45.9 vs. 33.9 months, HR 0.82, p = NT |
| ENDEAVOR * Kd vs. BOR-dex |
54 vs. 54 | NT for subgroup analysis | 15.6 vs. 8.1 months (HR 0.56, p = NT) | 41.8 vs. 32.7 months (HR 0.851, p = NT) |
| TOURMALINE MM1 * IRd vs. Rd |
69 vs. 69 | NT for subgroup analysis | 18.4 vs. 13.6 months (HR 0.74, p = NT) | 53.0 vs. 55.8 months (HR 0.994, p = NT) |
| EMN011/HOVON114 (Phase 2) K-POM-dex |
100% | 92 | 26 months | 67 months |
| APOLLO DARA-POM-dex vs. POM-dex |
47 vs. 49 | 69 vs. 46 ¶ | 8.3 vs. 6.3 months (HR = 0.73, p = NS, NT) | Data not yet mature |
| ICARIA ISA-POM-dex vs. POM-dex |
76.6 vs. 75.2 | 60.2 vs. 32.2 | 11.4 vs. 5.59 months (HR 0.578, p = NT) | Data not yet mature |
| ELOQUENT-3 (Phase 2) ELO-POM-dex vs. POM-dex |
78 vs. 82 | 53 vs. 26 ¶ | 10.2 vs. 4.7 months (HR 0.56, p = NT) ¥ | 28.3 vs. 16.0 months (HR 0.42, p = NT) ¥ |
Abbreviations: K—Carfilzomib, LEN—Lenalidomide, Dex—Dexamethasone, BOR—Bortezomib, I—Ixazomib, POM—Pomalidomide, DARA—Daratumumab, ISA—Isatuximib, ELO—Elotuzumab, NS—Not significant, Sig—Significant, NR—Not Reached, NT—Not Tabulated. * In ASPIRE, ENDEAVOR, and TOURMALINE MM1, the subgroup defined as previous Bortezomib exposure, not specifically refractory. Subgroups of patients defined as BOR refractory were small (1–2%). ¶ Intention to Treat population. ¥ Subgroup included dual LEN and PI refractory patients. Individual LEN refractory or PI refractory subgroups not reported.